Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 16Neoplasms 6Neoplasm Metastasis 3Carcinoma, Non-Small-Cell Lung 3Advanced Malignant Solid Tumors 3Lung Neoplasms 2Uterine Cervical Neoplasms 1Salivary Gland Neoplasms 1HER2+ Metastatic Breast Cancer (MBC) 1Cholangiocarcinoma 1Brain Neoplasms 1

Interventions

Temozolomide 29Bevacizumab 14Radiotherapy 12Trastuzumab 10Lomustine 9Capecitabine 8paclitaxel-Angiopep-2 conjugate 6Nivolumab 6pembrolizumab 5dabrafenib 5abemaciclib 5Radiation 5icotinib 4Surgical Procedures, Operative 4Paclitaxel 4Lapatinib 4Irinotecan 4Flucytosine 4Dianhydrogalactitol 4Corticotropin-Releasing Hormone 4Chlorotoxin 4Carboplatin 4vocimagene amiretrorepvec 3verubulin 3tucatinib 3osimertinib 3motexafin gadolinium 3XL647 3Spermine Synthase 3Radiosurgery 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Brain Neoplasms × neratinib × Clear all
NCT06374888 2024-04-19

Nilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastases

Convalife (Shanghai) Co., Ltd.

Phase 2 Not yet recruiting
28 enrolled
CNS

Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡